Materials
All the compounds used in the present study were commercially available,
including 2-(N-(7-Nitrobenz-2-oxa-1,3-diazol-4-yl)Amino)-2-Deoxyglucose
(2-NBDG, Invitrogen, USA, CID: 6711157), 2-deoxy-D-glocose (2DG,
Invitrogen, USA, CID: 5287471), cytochalasin B (Shanghai Yuanye
Bio-Technology Co., Ltd, China, CID: 5311281), metformin (Shanghai
Yuanye Bio-Technology Co., Ltd, China, CID: 4091), Dapagliflozin
(Shanghai Yuanye Bio-Technology Co., Ltd, China, CID: 9887712), ,
astragaloside IV (AST, Chengdu Mansit Bio-technology Co, Ltd, China,
CID: 13943297), and cycloastragalol (CAG, Chengdu Mansit Bio-technology
Co, Ltd, China, CID: 13943286). All detection kits were purchased from
Nanjing Jiancheng Bioengineering Institute (Nanjing, China), and ELISA
kits were obtained from Mlbio (USA). All other chemicals were of
analytical grade and were obtained from Sigma (USA) and Merck (DE).